Italia markets close in 4 hours 23 minutes

FTSE MIB
34.719,42
+380,10(+1,11%)
Dow Jones
39.387,76
+331,36(+0,85%)
Nasdaq
16.346,26
+43,46(+0,27%)
Nikkei 225
38.229,11
+155,13(+0,41%)
Petrolio
79,86
+0,60(+0,76%)
Bitcoin EUR
58.431,54
+2.090,82(+3,71%)

NVCR May 2024 17.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,1600

0,0000

(0,00%)

In data: 01:20PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in